Allergan Sues FDA over Ban on Off-Label Marketing of Botox

Under federal law, drug companies cannot market their products "off label," for the treatment of conditions that have not been approved by the U.S. Food & Drug Administration. Now one bold company is challenging that regulation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.